Open‐label, Investigator‐Initiated, Single Site Exploratory Trial Evaluating Secukinumab, an anti IL17A monoclonal antibody, for Patients with Moderate‐to‐Severe Hidradenitis Suppurativa

Abstract

Hidradenitis Suppurativa (HS) is a chronic inflammatory skin disease of the apocrine gland‐rich intertriginous areas.¹ HS lesions have an elevated Th17 immune response, and it is often challenging to treat patients, with existing therapies having limited efficacy.^2,3 We sought to investigate the role of secukinumab, a human monoclonal antibody that inhibits Interleukin‐17A, in HS treatment.

This article is protected by copyright. All rights reserved.

https://ift.tt/2T6ZIuU